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Abstract
Pancreatic cancer is associated with both family and hereditary cancer syndromes. Multigene panel testing for pancreatic 
cancer detected the germline variants BRCA1/2, PALB2, ATM, TP53, MLH1, STK11/LKB1, APC, CDKN2A, and SPINK1/
PRSS1 as high-risk genes. A latest genome-wide association study revealed the common, but low-risk germline variants in 
pancreatic cancer patients. Active pancreatic surveillance using magnetic resonance imaging and endoscopic ultrasound is 
recommended for high-risk individuals who have a family history of pancreatic cancer or harbor these germline pathogenic 
variants to improve the detection rate and prognosis of pancreatic cancer. Since poly-ADP-ribose polymerase (PARP) inhibi-
tor has been shown to be effective in improving the prognosis of BRCA -positive pancreatic cancer as well as hereditary 
breast and ovarian cancer syndrome, PARP inhibitor therapy is currently being applied as precision medicine to pancreatic 
cancer patients harboring the BRCA1/2 germline variant. This review highlights the importance of surveillance for germline 
pathogenic variants in pancreatic cancer and is expected to lead to improvements in the diagnosis and prevention of pancreatic 
cancer as well as facilitate the development of effective therapeutic strategies and precision medicine.
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Introduction
Pancreatic cancer is a multifactorial genetic disease. There 
are known germline pathogenic variants associated with 
hereditary pancreatic cancer, which is closely related to 
other hereditary tumor syndromes. Several high-risk factors 
have been identified, including family history of pancreatic 
cancer [1]. These risk factors are divided into modifiable, 
including smoking, daily alcohol consumption, chronic pan-
creatitis, diet, and obesity; and nonmodifiable, including age, 
gender, ethnicity, ABO blood group, diabetes, and family 
history (Fig. 1) [2–4]. Familial pancreatic cancer is defined 
as having two or more first-degree relatives (FDRs) with 
pancreatic cancer and accounts for approximately 3%–8.4% 
of all cases of this disease [5, 6]. Genome sequencing analy-
sis is used to investigate the germline variants of pancreatic 
cancers. In addition, genome-wide association analysis has 
identified common single nucleotide variants (SNVs) that 
are more frequently detected in pancreatic cancer.
Germline variant data can support early detection, pre-
vention, and personalized treatment of pancreatic cancer. 
Here, we highlight the most recently identified germline 
variants in pancreatic cancer, current management strate-
gies, and future perspectives for improving prognosis.
Hereditary pancreatic cancer related genes
Genes associated with hereditary cancer plays a key role 
in the development of pancreatic cancer [7–10]. The rela-
tionship between various hereditary cancer syndromes and 
pancreatic diseases is shown in Table 1. These pancreatic 
diseases can serve as prognostic determinants for each 
hereditary cancer syndrome.
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BRCA1/2
BRCA1 and BRCA2 are associated with hereditary breast 
and ovarian cancer syndrome (HBOC). HBOC follows an 
autosomal dominant pattern of inheritance and is character-
ized by early-onset breast and ovarian cancers. BRCA1/2 are 
DNA damage repair genes whose monoallelic or biallelic 
variants can cause HBOC or Fanconi anemia, respectively 
[11, 12]. Pathogenic BRCA carriers should undergo surveil-
lance for breast, ovarian, prostate, and pancreatic cancer 
as well as melanoma. The incidence of germline BRCA1/2 
pathogenic variants in pancreatic cancer is 5%–9% [13]. 
Moreover, the relative risk (RR) and cumulative incidence of 
pancreatic cancer for germline BRCA2 pathogenic variants 
are 3.5–10 and 2%–7%, and for germline BRCA1 pathogenic 
variants, 2.26 and 1%–3%, respectively [14].
PALB2
PALB2 (partner and localizer of BRCA2) is also involved 
in DNA damage repair and Fanconi anemia, which is 
strongly associated with breast, ovarian, and pancreatic 
cancer [15, 16]. PALB2 pathogenic germline variants are 
associated with a 7.18, 2.91, and 2.37 RR of developing 
female breast, ovarian, and pancreatic cancer, respectively, 
and their estimated incidence up to age 80 years is 53%, 
5%, and 2%–3%, respectively [17]. The latest American 
College of Medical Genetics and Genomics guidelines 
recommend that pancreatic cancer surveillance should be 
considered for germline PALB2 pathogenic variant [18].
ATM
ATM, whose biallelic variant can cause Ataxia-telangiectasia, 
plays a role similar to that of BRCA1/2 in DNA damage repair 
[19]. The ATM pathogenic germline variant is strongly associ-
ated with breast, ovarian, prostate, and pancreatic cancer. The 
RR for pancreatic cancer is 2.41 in individuals with the ATM 
germline pathogenic variant [20].
NBN
NBN is a DNA damage response gene, whose biallelic variant 
can cause severe microcephaly, infertility, and cancer. NBN 
pathogenic variants are mostly reported in breast cancer, but 
recent reports link them to pancreatic cancer as well. However, 
the cumulative incidence or RR has not been reported [16, 21].
TP53
The TP53 pathogenic variant is known to cause Li–Fraumeni 
syndrome, which is associated with a high risk of developing 
adrenocortical carcinomas, hematopoietic malignancies, breast 
cancer, central nervous system tumors, osteosarcomas, and 
soft-tissue sarcomas (https:// www. ncbi. nlm. nih. gov/ books/ 
NBK13 11/). The TP53 germline variant is associated with 
pancreatic cancer with RR of 7.3 [22].
Fig. 1  Relative risk and 
incidence of risk factors for 
pancreatic cancer. Pancreatic 
cancer has multiple mixed risk 
factors, including modifiable 
and nonmodifiable factors. 
These risk factors correlate 
with germline pathogenic vari-
ants. Very rare, but extremely 
high-risk germline variants 
(STK11/LKB1, TP53, and 
PRSS1/SPINK1) are usually 
detected using family linkage 
analysis, and rare and high-risk 
germline variants (BRCA1/2, 
ATM, PALB2, CDKN2A, MLH1, 
and APC) are detected using 
multigene panel testing. Com-
mon low-risk germline variants 
(GP2, and NOC2L) are detected 
using genome-wide associated 
studies
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Mismatch repair (MMR) genes (MLH1, MSH2, MSH6, 
PMS2)
Defective MMR genes, such as MLH1, MSH2, MSH6, and 
PMS2, display microsatellite instability and are the sus-
ceptibility genes of Lynch syndrome [23], a hereditary 
syndrome associated with an increased predisposition to 
colorectal, gastric, and endometrial cancers. The accu-
mulated risk of pancreatic cancer in Lynch syndrome is 
approximately 3.7%, which is slightly lower than that 
in HBOC [24]. The cumulative incidence of pancreatic 
Table 1  Relationship between germline variants and pancreatic diseases
Gene Hereditary cancer 
syndrome
Pancreatic disease(s) Relative risk 
for pancreatic 
cancer
Cumulative incidence 
of pancreatic cancer 
(%)
Phenotype References
BRCA1 Hereditary breast 
and ovarian cancer 
syndrome
Pancreatic cancer 2.26–3 1–3% (life-time risk) Breast, ovarian, and 
prostate cancer
[13, 14]
BRCA2 3.5–10 2–7% (life-time risk)
PALB2 – Pancreatic can-
cer Intraductal 
papillary mucinous 
neoplasm
2.37 2–3% (up to 80 years 
of age)
Breast, ovarian, and 
prostate cancer
[15, 17]
ATM – Pancreatic cancer 2.41 N.D Breast, ovarian, and 
prostate cancer
[18]
NBN – Pancreatic cancer N.D N.D Breast, ovarian, and 
prostate cancer
[15]
TP53 – Pancreatic cancer 7.3 N.D Adrenocortical car-
cinoma
[21]
Breast cancer
Central nervous 
system tumor
Osteosarcoma
Soft tissue sarcoma
MLH1 Lynch syndrome Pancreatic cancer 7.8 6.2% (up to 75 years 
of age)
Colorectal, gastric, 
and endometrial 
cancer
[24]
MSH2 0.6 0.5% (up to 75 years 
of age)
MSH6 1.8 1.4% (up to 75 years 
of age)
PMS2 N.D N.D
STK11/LKB1 Peutz-Jeghers syn-
drome
Pancreatic cyst 76.2 25.6% (up to 70 years 
of age)
Lip pigmentation 
Gastrointestinal 
polyposis
[25, 26]
Intraductal papillary 
mucinous neoplasm 
Pancreatic cancer
Colorectal, gastric, 
ovarian, breast, and 
cervical cancer
APC Familial adenoma-
tous polyposis
Pancreatic cyst 4.5 N.D Gastrointestinal 
polyposis
[27, 28]
Intraductal papillary 
mucinous neoplasm 
Pancreatic cancer
Colorectal and duo-
denal cancer
Desmoid tumor
CDKN2A Familial atypical 
multiple
Pancreatic cancer 13–39 17% (up to 75 years 
of age)
Malignant melanoma [30]
mole melanoma 
syndrome
Lung cancer
SMAD4/BMPR1A Juvenile polyposis 
syndrome
Pancreatic cancer N.D N.D Gastrointestinal 
polyposis
[30, 31]
PRSS1/SPINK1 Hereditary pancrea-
titis
Acute pancreatitis 
Chronic pancreatitis
53 40% (up to 70 years 
of age)
Pancreatitis [32]
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cancer in MLH1 carriers up to age 75 years is higher (RR 
7.8) than that observed for other MMR genes [25].
STK11/LKB1
The STK11/LKB1 germline variant accounts for approxi-
mately 90% of Peutz–Jeghers syndrome (PJS), which is a 
hereditary polyposis syndrome with an autosomal domi-
nant pattern of inheritance. PJS patients have increased 
risk of gastrointestinal and nongastrointestinal cancers and 
extremely high risk of developing early-onset pancreatic 
cancer. The cumulative risk for pancreatic cancer is 25.6% 
up to the age of 70 years (hazard ratio 76.2), and the mean 
age of onset is 40.8 (SD 16.2) years [26]. Further, lobular 
endocervical glandular hyperplasia and peritoneal pigmenta-
tion are caused by the STK11 germline variant [27].
APC
APC is a well-known susceptibility gene for familial adeno-
matous polyposis (FAP) [28], a hereditary polyposis syn-
drome with an autosomal dominant pattern of inheritance. 
Polyps occur mainly in the colon, but gastric, duodenum, 
and small bowel polyps are also frequent. The RR for pan-
creatic cancer is 4.5 times of the general population [29].
Cyclin‑dependent kinase inhibitor 2A (CDKN2A)
CDKN2A is a major susceptibility gene for familial atypi-
cal multiple mole melanoma syndrome (FAMMM), and 
FAMMM kindreds are at high risk of developing pancreatic 
cancer. Individuals with CDKN2A variants have a 70% life-
time risk of developing melanoma and a 17% risk of devel-
oping pancreatic cancer up to the age of 70 years [30]. The 
RR of developing pancreatic cancer was reported as 13–39 
for individuals with mutations in CDKN2A [31, 32]; how-
ever, there are no specific screening guidelines for FAMMM.
SMAD4 and BMPR1A
The SMAD4 germline variant is the most frequently recog-
nized in juvenile polyposis syndrome (JPS), along with the 
BMPR1A germline variant [33, 34]. Although the RR of 
pancreatic cancer in JPS is not as high as in other hereditary 
polyposis syndromes, careful management for preventing 
pancreatic cancer may be needed.
PRSS1 and SPINK1
PRSS1 is encoded by the cationic trypsinogen gene, and 
SPINK1 encodes the serine protease inhibitor Kazal 1. 
Hereditary pancreatitis is a rare disease that can progress to 
chronic pancreatitis. In Japan, the cumulative incidence of 
pancreatic cancer for hereditary pancreatitis with the PRSS1 
and SPINK1 variants was 40% up to the age of 70 years, and 
the RR for pancreatic cancer in hereditary pancreatitis was 
53 [35].
CPA1 and CPB1
CPA1 (encoding carboxypeptidase A1) and CPB1 (encod-
ing carboxypeptidase B1) can cause pancreatic acinar cell 
endoplasmic reticulum (ER) stress and these germline 
variants may lead to impaired secretion of its protein prod-
uct and induce ER stress. These variants are more com-
mon in patients with pancreatic cancer (approximately 
1% of individuals with pancreatic cancer when compared 
with < 0.001% in population controls), suggesting pancre-
atic acinar cell stress as a potential mechanism of pancreatic 
cancer susceptibility [36]
Multigene panel testing
Multigene panel testing is an effective tool for identifying 
germline pathogenic variants of pancreatic cancer. First, a 
National Familial Pancreas Tumor Registry (NFPTR; http:// 
patho logy. jhu. edu/ pancr eas/ nfptr/ index. php) analysis of the 
germline DNA of 638 familial pancreatic cancer patients 
from 593 kindreds revealed that germline pathogenic vari-
ants of ATM, BRCA2, CDKN2A, and PALB2 elevated the 
risk of pancreatic cancer, and that variants of BUB1B, CPA1, 
FANCC, and FANCG are detected more frequently in famil-
ial than in sporadic pancreatic cancer [37]. BRCA2 and ATM 
germline pathogenic variants are significantly more preva-
lent in familial pancreatic cancer patients [38]. Furthermore, 
using linkage analysis, the palladin gene was reported as a 
new germline pathogenic variant in 2006 [39].
New germline pathogenic variants were described in 
Japanese familial pancreatic cancer patients [40]. In whole-
exome sequencing of germline DNA from whole blood of 
81 patients, ATM and BRCA2 were recognized in 7 (8.6%) 
and 3 (3.7%) patients, respectively. Furthermore, ASXL1 
or DNMT3A, which are tumor suppressor genes, were also 
identified as germline variants of familial pancreatic can-
cer. Interestingly, new germline susceptibility genes, FAT1 
(n = 4) and FAT4 (n = 3), which encode the large transmem-
brane proteins protocadherins, were discovered in seven 
patients [40]. Therefore, familial pancreatic cancer has a 
wide range of germline variants instead of a predominant 
gene such as BRCA1/2 in HBOC or APC in FAP. Thus, 
multigene panel testing for pancreatic cancer patients may 
be able to provide substantial information about high-risk 
pathogenic germline variants common to previously known 
hereditary cancer syndromes.
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Low‑risk germline variants 
and environmental factors
Genome-wide association studies (GWASs) have led to the 
discovery of common and low-risk germline variants in 
pancreatic cancer patients. A meta-analysis of GWASs con-
ducted in Europe and the United States reported that an SNV 
of NOC2L (1p36.33, rs13303010) was significantly associ-
ated with pancreatic cancer [41]. A GWAS conducted in 
East Asia, including Japan and China, reported that an SNV 
of GP2 (16p12.3, rs78193826), which is common in patients 
with pancreatic cancer is also strongly involved in KRAS 
activity [42]. Hence, it is important to recognize the envi-
ronmental risk factors for pancreatic cancer because they 
can be modulated/targeted to prevent malignant progression.
Registries for familial pancreatic cancer
Familial pancreatic cancer is as important as hereditary pan-
creatic cancer because a family history of pancreatic cancer 
places an individual at an extremely high risk of pancreatic 
cancer development. Familial pancreatic cancer was first 
reported in 1976 in the United States [43], leading to the 
suggestion of a genetic component. In 1994, the NFPTR 
was established by researchers in Johns Hopkins University, 
and prospective registration of familial pancreatic cancer 
was initiated (Table 2) [44, 45]. Subsequently, the European 
Registry of Hereditary Pancreatitis and Familial Pancreatic 
Cancer (EUROPAC, https:// www. lctu. org. uk/ LCTU_ NET/ 
front end/ Defau lt. aspx? Data= W1tiR zlqWV d4bF1 dW09R 
PT1d) was established in 1997 in the United Kingdom, and 
the German National Case Collection for Familial Pancreatic 
Carcinoma (FaPaCa, http:// www. fapaca. de/) was introduced 
in 1999. The PanGen-Fam registry was established in Spain 
in 2009 to identify families with high PDAC risk [46]. In 
Japan, the registration system was initiated in 2014 as the 
Japan Familial Pancreatic Cancer Registry (JFPCR, http:// 
jfpcr. com/) [47].
The first epidemiological study of NFPTR revealed that 
the risk in familial pancreatic cancer kindreds was elevated 
in individuals with three (odds ratio 32.0), two (odds ratio 
6.4), or one (odds ratio 4.6) FDR(s) with pancreatic cancer 
[48, 49]. Next, the large EUROPAC cohort study in 2006 
demonstrated that patients with familial pancreatic cancer 
experienced early onset of pancreatic cancer and were likely 
to be deceased younger than patients with sporadic pancre-
atic cancer, which was expressed as anticipation [50]. Third, 
FaPaCa showed that 74% of familial pancreatic cancer has 
an autosomal dominant inheritance pattern, and familial pan-
creatic cancer is frequently concomitant with breast cancer 
[51]. The analysis of the PanGen-Fam registry indicated that 
family history of cancer and diabetes increased the risk of 
pancreatic cancer development [52]. Thus, since the risk of 
developing pancreatic cancer is extremely high in cases with 
a strong family history, familial and hereditary pancreatic 
cancer cases should be approached aggressively.
Surveillance for pathogenic germline variant 
carriers
Pancreatic cancer has one of the highest mortality rates 
among all types of malignant solid tumor. The 5-year over-
all survival is 9%–13% [53], and only approximately 25% of 
tumors are resectable [54]. Most patients display no symp-
toms and undergo rapid progression [55]. Thus, early diag-
nostic management and intervention is a must for improving 
outcomes.
The international cancer of the pancreas screening 
(CAPS) consortium proposed a concise strategy for pan-
creatic surveillance of high-risk individuals to improve the 
rate of detection at an early stage [56]. According to CAPS, 
the best imaging techniques for routine follow-ups are endo-
scopic ultrasound (EUS) and magnetic resonance imaging 
or cholangiopancreatography (MRI/MRCP) because of their 
higher sensitivity and specificity than that of computed 
tomography [57, 58]. It is suggested that these screenings 
should be initiated at the age of 30–35 years or 10 years 
younger than the earliest exocrine pancreatic cancer diagno-
sis in the family, especially for patients with PJS [6, 59], but 
the best timing to start screening of the pancreas for high-
risk individuals remains to be established (Table 3) [60].
Table 2  Familial pancreatic 
cancer registry worldwide
Registration Year of establish-
ment
Country References
National Familial Pancreas Tumor Registry 1994 United States [19, 20]
The European Registry of Hereditary Pancreatitis 
and Familial Pancreatic Cancer
1997 United Kingdom [21]
The German National Case Collection for Famil-
ial Pancreatic Carcinoma
1999 Germany [22]
PanGen-Fam Registry 2009 Spain [23]
Japan Familial Pancreatic Cancer Registry 2014 Japan [18]
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This surveillance is also recommended for individuals 
with three or more blood relatives with pancreatic cancer, 
and at least one of those affected FDR carrying the BRCA2 
or PALB2 germline pathogenic variant. Surveillance should 
be considered for individuals with two affected blood rela-
tives with pancreatic cancer or with at least one FDR [56]. 
In a 2018 study, during the median 5.6-year follow-up, 14 
(4.0%) and 10 (2.8%) patients of the 354 high-risk individu-
als developed pancreatic cancer and high-grade dysplasia, 
including IPMN, respectively. The resection rate of the pan-
creatic cancers was 71.4%, and the 5-year overall survival 
rate was 60%, which is much better than the reported sur-
veillance, epidemiology, and end results in the United States 
[61]. As this aggressive surveillance has a favorable progno-
sis, the latest NCCN guidelines also recommend EUS, MRI, 
and MRCP twice a year for high-risk individuals [62]. It is 
important to explore other diagnostic modalities including 
biomarkers to improve outcomes in the near future.
Drug sensitivity
Poly‑ADP‑ribose polymerase (PARP) inhibitors
PARP inhibitors play a key role in the induction of double-
stranded breaks after the collapse of the DNA replication 
process. The efficacy of PARP inhibitors against advanced 
breast, ovarian, pancreatic, and prostate cancer with a 
BRCA1/2 pathogenic variant was recognized in 2015 [63]. 
When compared with placebos, PARP inhibitors resulted in 
longer progression-free survival for BRCA -positive meta-
static pancreatic cancer following platinum-based chemo-
therapy [63, 64]. Hence, PARP inhibitors are used as main-
tenance therapy and BRCA genetic testing for pancreatic 
cancer is a companion diagnosis.
Immune checkpoint inhibitors
Pembrolizumab, an immune checkpoint inhibitor, has a criti-
cal impact and benefits the survival of patients with germline 
pathogenic variants of MMR genes [65]. Although only a 
small proportion (approximately 1%) of pancreatic cancer 
patients have these MMR genes, it is important to assess the 
potential efficacy of pembrolizumab in hereditary pancreatic 
cancer [66].
Platinum
Patients with strong family history of breast, ovarian, and 
pancreatic cancer have better prognoses than those without 
such history and are sensitive to platinum-based chemother-
apy [67]. However, a prospective Phase II study from Japan 
revealed that gemcitabine plus oxaliplatin did not produce 
a favorable outcome in patients with metastatic pancreatic 
cancer with a family history of breast, ovarian, and pan-
creatic cancer [68]. BRCA germline pathogenic variants are 
prognostic and therapeutic biomarkers in breast and ovar-
ian cancer, and platinum-based chemotherapy is a standard 
treatment for these cancers [68]. As the overall survival for 
stage-3 or -4 BRCA -mutated pancreatic cancer was improved 
by platinum-based treatment [69], HBOC pancreatic cancer 
patients are good candidates for platinum-based therapy.
Future perspectives for hereditary 
pancreatic cancer
There is no standard conceptualization about the disclosure 
of germline pathogenic variants. As mentioned earlier, it is 
possible to detect various types of deleterious variants in 
the DNA of familial pancreatic cancer patients. These need 
to be carefully analyzed to decide how to proceed with dis-
ease management [70]. Deleterious variants have also been 
reported in ~ 5%–10% of patients with apparently sporadic 
pancreatic cancer [31, 71]. Because of these papers, recent 
NCCN guidelines recommend offering genetic testing for 
patients with newly diagnosed pancreatic ductal adenocarci-
noma [62] In addition, optimal surveillance is needed similar 
to that for HBOC syndrome, because pancreatic lesions are 
not usually found in routine medical check-ups [72].
It is difficult to predict germline pathogenic variants from 
a family history of pancreatic cancer. For example, when 
306 pancreatic cancer patients were screened for BRCA 
genetic analysis, 14 (4.6%) were positive, of which only two 
Table 3  High-risk individuals 
for pancreatic cancer
Subject categories Start screening 
[59, 62] (age in 
years)
Three or more first- and/or second- degree relatives with pancreatic cancer 50
Two or more first-degree relatives with pancreatic cancer 50
Pathogenic germline variant carrier and a family history of pancreatic cancer (ATM, 
BRCA1, BRCA2, MLH1, MSH2, MSH6, EPCAM, PALB2, TP53)
50
Individuals with pathogenic germline variant in STK11 30–35
Individuals with pathogenic germline variant in CDKN2A 40
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had family history of pancreatic cancer, indicating that the 
absence of family history of pancreatic cancer does not mean 
that BRCA testing should not be performed [73]. BRCA2, 
ATM, and BRCA1 were detected, in that order, from blood 
samples of 1 009 pancreatic cancer patients. However, the 
prediction of germline variants from clinical information 
such as sex, past medical history, and family history—easy 
for breast cancer—is extremely difficult for pancreatic cancer 
[74]. Furthermore, a recent study has revealed that harboring 
a pathogenic, or likely pathogenic variant is associated with 
a greater incidence of pancreatic cancer than family history 
alone (without the presence of an associated germline vari-
ant) [75]. Therefore, while hereditary and familial pancreatic 
cancer overlap in some cases, they must be considered as 
similar but different domains.
Finally, preventive total pancreatectomy for individuals 
with BRCA1/2 germline pathogenic variants has not been 
allowed, as it can result in severe and potentially fatal com-
plications, including insulin-dependent diabetes, pancreatic 
enzyme insufficiency, and blood glucose instability. Con-
versely, in the recent years, medical developments have led 
to better control of total pancreatectomy treatment and a 
trend toward low complication and mortality rates. There-
fore, in Europe, it has been suggested that the decision pro-
gram of prophylactic total pancreatectomy could be useful 
in high-risk individuals of pancreatic cancers such as heredi-
tary pancreatitis and IPMN with STK11/LKB1 or CDKN2A 
pathogenic variants [76].
Conclusion
A deeper understanding of hereditary pancreatic cancer is 
crucial in improving strategies for detecting pancreatic can-
cer more frequently at an early stage and preventing malig-
nant progression. Multigene panel testing or whole-genome 
sequencing should be performed for identifying germline 
pathogenic variants. Continuously updating the current 
knowledge base of hereditary pancreatic cancer syndromes 
will aid in the development of potential diagnostic and prog-
nostic measures, resulting in more favorable outcomes.
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